Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRIW) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Biofrontera (BFRIW) over the last 6 years, with Q3 2025 value amounting to $30000.0.

  • Biofrontera's Other Non Operating Income rose 19375.0% to $30000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$333000.0, marking a year-over-year increase of 3091.29%. This contributed to the annual value of -$316000.0 for FY2024, which is 32133.33% down from last year.
  • Per Biofrontera's latest filing, its Other Non Operating Income stood at $30000.0 for Q3 2025, which was up 19375.0% from -$264000.0 recorded in Q2 2025.
  • Biofrontera's Other Non Operating Income's 5-year high stood at $270000.0 during Q4 2021, with a 5-year trough of -$316000.0 in Q1 2024.
  • Its 5-year average for Other Non Operating Income is -$1611.1, with a median of $14500.0 in 2022.
  • The largest annual percentage gain for Biofrontera's Other Non Operating Income in the last 5 years was 25909.09% (2023), contrasted with its biggest fall of 476666.67% (2023).
  • Quarter analysis of 5 years shows Biofrontera's Other Non Operating Income stood at $270000.0 in 2021, then crashed by 98.89% to $3000.0 in 2022, then plummeted by 4766.67% to -$140000.0 in 2023, then soared by 77.14% to -$32000.0 in 2024, then skyrocketed by 193.75% to $30000.0 in 2025.
  • Its Other Non Operating Income was $30000.0 in Q3 2025, compared to -$264000.0 in Q2 2025 and -$99000.0 in Q1 2025.